OncoMatch/Clinical Trials/NCT07006506
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Is NCT07006506 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Belumosudil for graft versus host disease.
Treatment: Belumosudil — The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Cannot have received: belumosudil (belumosudil)
Prior therapy with belumosudil
Cannot have received: in vivo T cell depletion (anti-thymocyte globulin)
Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin)
Lab requirements
Blood counts
Engraftment: ANC≥500/μL and platelets ≥ 20000/μL on 3 consecutive measurements (each at least 1 day apart, no platelet transfusion within 7 days before first measurement)
Kidney function
GFR ≥ 30 mL/min/1.73 m2
Liver function
ALT and AST ≤ 3x ULN; total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia)
Engraftment is defined as ANC≥500/μL and platelets ≥ 20000/μL on 3 consecutive measurements (each occurring at least 1 day apart). ALT and AST ≤ 3x ULN; total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia). GFR ≥ 30 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07006506 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior belumosudil, in vivo T cell depletion disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify